Brian O Mahony/X
Sep 13, 2025, 13:34
Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
“Nugent BIC2025 presents 5 year data on valoctocogene roxaparvovec (Roctavian) GENE R-8 1 trial.
128 of 134 participants completed the trial. Using chromogenic assay at 5 years, mean FVIII 13.7, median 6.2 IU/dl 1/3”
Stay informed with Hemostasis Today.
-
Feb 2, 2026, 17:54Danny Gaskin: Nominations are Open for the BBTS Transfusion Practitioner Special Interest Group Award 2026
-
Feb 2, 2026, 17:44Important Webinar on Care for Patients with iTTP – ISTH
-
Feb 2, 2026, 17:21Tagreed Alkaltham: Some Risks Don’t Look Like Risks in Healthcare
-
Feb 2, 2026, 17:16Sifat Jubaira: Effect of Prolonged Tourniquet Application
-
Feb 2, 2026, 17:14Vivek Mahto: Understanding Deep Vein Thrombosis – Causes, Symptoms, and Prevention
-
Feb 2, 2026, 17:08Tareq Abadl: Heparin vs Warfarin
-
Feb 2, 2026, 17:07Mary Cushman: New Research on Aspirin Use in Pregnancy and Stroke Risk in Offspring
-
Feb 2, 2026, 16:52Aravind Palraj: Young Stroke is Never Just Stroke
-
Feb 2, 2026, 16:48Seyed Mohsen Jahromi Moghadam: Antithrombotic Therapy After Transcatheter Structural Heart Interventions